inactivation pi3k p110 delta breaks regulatory t-cell-mediated immune tolerance cancer 
inhibitors thep110 delta isoform phosphoinositide--oh kinase pi3 k shown remarkable therapeutic efficacy human leukaemias12 p110 delta primarily expressed leukocytes3 drugs p110 delta considered treatment solid tumours4 report p110 delta inactivation mice protects broad range cancers including non-haematological solid tumours demonstrate p110 delta inactivation regulatory t cells unleashes cd8+ cytotoxic t cells induces tumour regression thus p110 delta inhibitors can break tumour-induced immune tolerance considered wider use oncology 
